← Indivior Pharmaceuticals, Inc. INDV
Market Price
$39.00
Market Cap
$4.52B
P/E Ratio
23.78
Revenue (FY 2025)
↑4.3% YoY
$1.24B
3-Yr CAGR: 11.2%
Net Income
↑10,400.0% YoY
$210.00M
Net Margin: 16.9%
Free Cash Flow
↓-1,428.6% YoY
-$93.00M
FCF Yield: -2.06%
EPS (Diluted)
↑8,100.0% YoY
$1.64
Basic: $1.68
Return on Equity
Efficiency
N/A
ROA: 17.5%
⚡ N/A due to negative equity (share buybacks or other)
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (INDV)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2020 | — | — | — | — | — | — | — | — | — | — |
| FY 2021 | $791.0M | — | $664.0M | $205.0M | — | $1.35 | — | $353.0M | $349.0M | — |
| FY 2022 | $901.0M | +13.9% | $742.0M | $-53.0M | -125.9% | $-0.38 | -128.1% | $-4.0M | $-9.0M | -102.6% |
| FY 2023 | $1,093.0M | +21.3% | $907.0M | $2.0M | +103.8% | $0.01 | +102.6% | $-315.0M | $-323.0M | -3,488.9% |
| FY 2024 | $1,188.0M | +8.7% | $957.0M | $2.0M | 0.0% | $0.02 | +100.0% | $36.0M | $7.0M | +102.2% |
| FY 2025 | $1,239.0M | +4.3% | $993.0M | $210.0M | +10,400.0% | $1.64 | +8,100.0% | $-27.0M | $-93.0M | -1,428.6% |
Valuation
Market Price
$39.00
Market Cap
$4.52B
Enterprise Value
$4.67B
P/E Ratio
23.78
P/B Ratio
N/A
FCF Yield
-2.06%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
80.15%
Operating Margin
21.15%
Net Margin
16.95%
Return on Equity (ROE)
N/A (Negative Equity)
Return on Assets (ROA)
17.49%
Asset Turnover
1.03x
Revenue 3-Yr CAGR
11.20%
Financial Health & Liquidity
Current Ratio
0.71
Cash Ratio
0.21
Debt / Equity
-3.582
Debt / Assets
0.292
Cash & Equivalents
$195.00M
Total Debt
$351.00M
Book Value / Share
$-0.83
Cash Flow Efficiency
Operating Cash Flow
-$27.00M
Capital Expenditures (CapEx)
$66.00M
Free Cash Flow
-$93.00M
OCF / Revenue
-2.18%
FCF / Revenue
-7.51%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$1.64
EPS (Basic)
$1.68
Dividends / Share
N/A
Book Value / Share
$-0.83
EPS YoY Growth
8,100.00%
Balance Sheet (FY 2025)
Total Assets
$1.20B
Total Liabilities
$1.30B
Stockholders' Equity
-$98.00M
Current Assets
$652.00M
Current Liabilities
$914.00M